检索结果 - Gordon Cook
- Showing 1 - 20 results of 93
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma 由 M von Lilienfeld-Toal, Corinna Hahn‐Ast, Kerstin Furkert, Florian Hoffmann, Ralph Naumann, Ralf C. Bargou, Gordon Cook, Axel Glasmacher
出版 2008Revisão -
8
-
9
-
10
CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells are increased whilst CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup>αβTCR<sup>+</sup> Double Negative T cells are... 由 Sylvia Feyler, M von Lilienfeld-Toal, Sarah Jarmin, Lee Marles, Andy C. Rawstron, A. John Ashcroft, Roger G. Owen, Peter J. Selby, Gordon Cook
出版 2009Artigo -
11
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation 由 David I. Marks, Antonio Pagliuca, Christopher C. Kibbler, Axel Glasmacher, Claus Peter Heußel, Michal Kantecki, Paul Miller, Patricia Ribaud, Haran T. Schlamm, Carlos Solano, Gordon Cook
出版 2011Artigo -
12
Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma 由 Kirsty Thomson, Emma Morris, Adrian Bloor, Gordon Cook, Don Milligan, Anne Parker, Fiona Clark, Lynny Yung, David C. Linch, Ronjon Chakraverty, Karl S. Peggs, Stephen Mackinnon
出版 2008Artigo -
13
Utility of a Commercially Available Multiplex Real-Time PCR Assay To Detect Bacterial and Fungal Pathogens in Febrile Neutropenia 由 Marie von Lilienfeld‐Toal, Lutz Lehmann, Ansgar Raadts, Corinna Hahn‐Ast, Katjana Orlopp, G. Marklein, Ingvill Purr, Gordon Cook, Andreas Hoeft, Axel Glasmacher, Frank Stüber
出版 2009Artigo -
14
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial 由 Rakesh Popat, Sarah Brown, Louise Flanagan, Andrew Hall, Walter M. Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh
出版 2016Artigo -
15
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Bl... 由 Gordon Cook, Graeme Smith, Keiren Kirkland, Jungwha Lee, Rachel Pearce, Kirsty Thomson, Emma Morris, Kim Orchard, Simon Rule, Nigel H. Russell, Charles Craddock, David I. Marks
出版 2010Artigo -
16
IgM myeloma: a rare entity characterized by a CD20<sup>−</sup>CD56<sup>−</sup>CD117<sup>−</sup> immunophenotype and the t(11;14) 由 Sylvia Feyler, Sheila J.M. O’Connor, Andy C. Rawstron, Chezhian Subash, Fiona M. Ross, Guy Pratt, Mark T. Drayson, John Ashcroft, Gordon Cook, Roger G. Owen
出版 2008Artigo -
17
-
18
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study 由 Julio Delgado, Kirsty Thomson, Nigel H. Russell, Joanne Ewing, Wendy A. Stewart, Gordon Cook, Stephen Devereux, Richard Lovell, Rajesh Chopra, David I. Marks, Stephen Mackinnon, Donald Milligan
出版 2005Artigo -
19
Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantatio... 由 Gordon Cook, Effie Liakopoulou, Rachel Pearce, Jim Cavet, Gareth J. Morgan, Keiren Kirkland, Julia Lee, Faith E. Davies, R. Hall, Amin Rahemtulla, Nigel H. Russell, David I. Marks
出版 2011Artigo -
20
T-Cell–Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patient... 由 Kirsty Thomson, Emma Morris, Don Milligan, Anne Parker, Ann E. Hunter, Gordon Cook, Adrian Bloor, Fiona Clark, Majid Kazmi, David C. Linch, Ronjon Chakraverty, Karl S. Peggs, Stephen Mackinnon
出版 2010Artigo
相关主题
Medicine
Internal medicine
Multiple myeloma
Oncology
Biology
Surgery
Transplantation
Clinical trial
Immunology
Chemotherapy
Genetics
Lenalidomide
Dexamethasone
Cyclophosphamide
Adverse effect
Confidence interval
Disease
Gene
Intensive care medicine
Melphalan
Gastroenterology
Bortezomib
Stem cell
Autologous stem-cell transplantation
Daratumumab
Environmental health
Hematopoietic stem cell transplantation
Population
Regimen
Thalidomide